UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

The Lancet. Rheumatology, 2022-03, Vol.4 (3), p.e154-e155

2022

Volltextzugriff (PDF)

Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic

Arthritis research & therapy, 2021-08, Vol.23 (1), p.207-207, Article 207

2021

Volltextzugriff (PDF)

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

Annals of the rheumatic diseases, 2015-01, Vol.74 (1), p.311-314

2015

Volltextzugriff (PDF)

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

Alimentary pharmacology & therapeutics, 2008-11, Vol.28 (9), p.1122-1126

2008

Volltextzugriff (PDF)

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

Annals of the rheumatic diseases, 2010-05, Vol.69 (5), p.817-821

2010

Volltextzugriff (PDF)

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

Annals of the rheumatic diseases, 2012-01, Vol.71 (1), p.88-91

2012

Volltextzugriff (PDF)

Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study

Annals of the rheumatic diseases, 2010-03, Vol.69 (3), p.490-494

2010

Volltextzugriff (PDF)

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2005-05, Vol.64 (5), p.704-707

2005

Volltextzugriff (PDF)

Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

Clinical rheumatology, 2013-10, Vol.32 (10), p.1429-1435

2013

Volltextzugriff (PDF)

Elevated Fab glycosylation of anti-hinge antibodies

Scandinavian journal of rheumatology, 2023-01, Vol.52 (1), p.25-32

2023

Volltextzugriff (PDF)

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial

Scandinavian journal of rheumatology, 2023-03, Vol.52 (2), p.129-136

2023

Volltextzugriff (PDF)

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up

PloS one, 2018-10, Vol.13 (10), p.e0205125-e0205125

2018

Volltextzugriff (PDF)

A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides

Annals of the rheumatic diseases, 2015-03, Vol.74 (3), p.e15-e15

2015

Volltextzugriff (PDF)

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium

Annals of the rheumatic diseases, 2008-08, Vol.67 (8), p.1139-1144

2008

Volltextzugriff (PDF)

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

Annals of the rheumatic diseases, 2009-04, Vol.68 (4), p.531-535

2009

Volltextzugriff (PDF)

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

Annals of the rheumatic diseases, 2015-02, Vol.74 (2), p.361-368

2015

Volltextzugriff (PDF)

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2010-02, Vol.69 (2), p.409-412

2010

Volltextzugriff (PDF)

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

Annals of the rheumatic diseases, 2010-03, Vol.69 (3), p.624-625

2010

Volltextzugriff (PDF)

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

Annals of the rheumatic diseases, 2007-02, Vol.66 (2), p.253-256

2007

Volltextzugriff (PDF)

Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies

Annals of the rheumatic diseases, 2015-10, Vol.74 (10), p.1915-1923

2015

Volltextzugriff (PDF)

Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

Annals of the rheumatic diseases, 2015-10, Vol.74 (10), p.1825-1829

2015

Volltextzugriff (PDF)

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis

Scandinavian journal of rheumatology, 2019-07, Vol.48 (4), p.266-270

2019

Volltextzugriff (PDF)

Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)

Pediatric rheumatology online journal, 2021-04, Vol.19 (1), p.59-59, Article 59

2021

Volltextzugriff (PDF)

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

Annals of the rheumatic diseases, 2009-11, Vol.68 (11), p.1787-1788

2009

Volltextzugriff (PDF)

POS0524 CARDIOVASCULAR DISEASE RISK IN INFLAMMATORY ARTHRITIS PATIENTS STILL SUBSTANTIALLY ELEVATED IN 2020

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.495-496

2021

Volltextzugriff (PDF)

1 – 25 von 221

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(202)
Mit Volltextzugriff
(159)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(119)
Science & Technology
(115)
Life Sciences & Biomedicine
(113)
Rheumatology
(83)
Male
(71)
Female
(69)
Middle Aged
(66)
Rheumatoid Arthritis
(58)
Adult
(55)
Biological And Medical Sciences
(51)
Medical Sciences
(47)
Aged
(39)
Arthritis, Rheumatoid - Drug Therapy
(39)
Patients
(33)
Antirheumatic Agents - Therapeutic Use
(31)
Infliximab
(30)
Tumor Necrosis Factor-Tnf
(30)
Diseases Of The Osteoarticular System
(29)
Antibodies, Monoclonal - Therapeutic Use
(27)
Prospective Studies
(27)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

Elevated Fab glycosylation of anti-hinge antibodies

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up

A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies

Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis

Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

POS0524 CARDIOVASCULAR DISEASE RISK IN INFLAMMATORY ARTHRITIS PATIENTS STILL SUBSTANTIALLY ELEVATED IN 2020

Suchergebnisse filtern